Market Research Report
Inflammatory Bowel Disease (IBD) Deals Analytics Report, 2010-2019
|Published by||GervanoRA Data Services LLP||Product code||832999|
|Published||Content info||43 Pages
Delivery time: 1-2 business days
|Inflammatory Bowel Disease (IBD) Deals Analytics Report, 2010-2019|
|Published: April 30, 2019||Content info: 43 Pages||
GervanoRA's Inflammatory Bowel Disease (IBD) Deals Activity Report, 2010-2019 has analyzed and provided an understanding of the overall competition in partnering landscape in the disease area that has occurred from the year 2010.
GervanoRA has analyzed more than 170 drug candidates in the current development pipeline. Hence, a number of emerging and clinical-stage companies are embarking with collaborations or partnerships with different pharma companies to aid in the development process of their respective drug candidates. In the light of rocketing competition, not only companies, but also universities, institutes and research centers are getting actively involved in the advancements of new medicines for the treatment of the disease.
The report through its meticulous analysis on global therapeutic landscape of IBD deals assists companies in taking future partnering decisions based on competitor's R&D activities; current trends in partnering landscape in order to avoid or mitigate competitive market risks.
For a proper understanding, GervanoRA has segmented the report into sections based on:
The report also includes case studies provided for the deals that were prominent and unique among all the deals.
DEAL 1: CELGENE TO ACQUIRE RECEPTOS, ADVANCING LEADERSHIP IN IMMUNE-INFLAMMATORY DISEASES
DEAL 2: GALAPAGOS AND GILEAD ANNOUNCE GLOBAL PARTNERSHIP TO DEVELOP FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES
DEAL 3: NOVARTIS TO ACQUIRE IFM TRE TO DEVELOP FIRST-IN-CLASS NLRP3 ANTAGONIST PORTFOLIO TARGETING INNATE IMMUNE SYSTEM
DEAL 04: ASTRAZENECA AND ORCA PHARMACEUTICALS ANNOUNCE RESEARCH COLLABORATION TO IDENTIFY BEST-IN-CLASS RORΓ INHIBITORS TO TREAT AUTO-IMMUNE DISEASES
DEAL 05: BIOMX LICENSES NOVEL BACTERIAL TARGETS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE